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Figure 7. 
The MS Data for P4 Glycoside and Aglycone. 
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Isolation scheme for anti-inflammatory and anti-oxidant compounds from C. 
cunninghamii. 
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BIOLOGICALLY ACTIVE COMPOUNDS 
FIELD OF THE INVENTION 
This invention relates to compounds having useful biologi 
cal activity; more speci?cally to compounds having antioxi 
dant and anti-in?ammatory activity. In particular, this inven 
tion relates to such biologically active compounds derived 
from Cenlipeda cunninghamii, and biologically active 
derivatives thereof. 
BACKGROUND OF THE INVENTION 
The reference to any prior art in this speci?cation is not, 
and should not be taken as, an acknowledgment or any form 
of suggestion that that prior art forms part of the common 
general knowledge in Australia. 
There is at the present time a signi?cant medical need for 
new anti-in?ammatory and anti-arthritic drugs with reduced 
side effects and prolonged in vivo activity and in particular for 
compounds which will moderate the progress of the arthro 
pathies. Plants and other living cells offer a vast reservoir of 
compounds which have pharmacological effects on humans. 
Natural products have frequently been the source of effective 
drugs and lately there has been an increased interest in the 
analysis of these natural products, especially where a clinical 
bene?t is claimed. 
Cenlipeda cunninghamii and related plant species have 
been used by the Aboriginal people of Australia for many 
generations in the treatment and prevention of many ailments. 
C. cunninghamii is commonly known as Gukwonderuk, 
koona puturku, sneeZeweed, old man weed or scent wood. C. 
cunninghamii is known to grow primarily in the lower tem 
perate regions of south-eastem Australia. It is commonly 
found along stream banks and in the back wash of rivers or 
streams where the water is stagnant. 
Traditionally, C. cunninghamii has been used by the 
Aboriginal people as an aqueous infusion or tea, which has 
either been taken orally or used directly on the skin. Although 
C. cunninghamii has beenused by theAboriginal people there 
is little known about this plant and the active component(s) 
responsible for its various properties. 
International Patent Application No. PCT/AU98/0003l 
(WO 98/ 32454), the content of which is incorporated herein 
by reference, discloses compositions comprising an extract 
from plants in the genus Cenlipeda, more particularly an 
aqueous alcoholic extract of C. cunninghamii or a related 
Cenlipeda species useful in the effective treatment and pro 
phylaxis of many types of medical problems as well as for 
cosmetic applications. 
SUMMARY OF THE INVENTION 
As described above, the present invention relates to bio 
logically active compounds derived from Cenlipeda cunning 
hamii, and biologically active derivatives thereof. 
In one aspect, the present invention provides a compound 
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wherein W is a monosaccharide group selected from pentose 
and hexose sugars in pyranose or furanose form, a substi 
tuted monosaccharide group in which one or more of the 
iOH groups of a said pentose or hexose sugar is replaced 
by an iORl group or a disaccharide group comprising two 
of said monosaccharide or substituted monosaccharide 
groups linked by a glycosidic bond; 
wherein each R, which may be same or different, is selected 
from the group consisting of hydrogen and R1; and 
each R1, which may be the same or different, is selected from 
the group consisting of substituted or unsubstituted alkyl, 
substituted or unsubstituted cycloalkyl, substituted or 
unsubstituted cycloalkylalkyl, substituted or unsubstituted 
aryl, substituted or unsubstituted arylalkyl, a protecting 
group, 4C(O)iR“, iC(O)OiR“, 4C(O)NR“R“i, 
is (O)niR“ and is (O)niNR“R“ (wherein n represents 
1 or 2, and R“ is selected from the group consisting of 
hydrogen and substituted or unsubstituted alkyl); and their 
pharmaceutically acceptable salts. 
Preferably in the compounds of Formulae I and II, R1 is 
selected from hydrogen and alkyl. 
In another aspect, the present invention also provides a 
compound selected from: 
(i) 2',4',5,7-tetrahydroxy-6-methoxy?avone-3-O-[3-glucopy 
ranoside (Compound 1) 
(ii) 4E,5E-Di-O-caffeoyl-2,6E-dihydroxyhept-2-en-l ,7-dioic 
acid (Compound 2) 
(iii) 4%,5E-Di-O-caffeoyl-2,6E-dihydroxyhept-2 -en-l ,7 
dioic acid-7-methyl ester (Compound 8) 
(iv) 4%,5E-Di-O-caffeoyl-2,6E-dihydroxyhept-2 -en-l ,7 
dioic acid-l -methyl ester (Compound 9) 
(v) 4%,5E-Di-O-caffeoyl-2,6E-dihydroxyhept-2-en-l,7-dioic 
acid-dimethyl ester (Compound 10) 
in substantially puri?ed form, and pharmaceutically accept 
able salts thereof. 
In a further aspect, the present invention provides a method 
of antioxidant or anti-in?ammatory treatment of a human or 
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other mammal, Which comprises administration to said 
human or other mammal of a therapeutically effective amount 
of a compound of Formula I or Formula II above, or a phar 
maceutically acceptable salt thereof. 
In a particular embodiment, the invention provides a 
method of antioxidant or anti-in?ammatory treatment of a 
human or other mammal, Which comprises administration to 
said human or other mammal of a therapeutically effective 
amount of a compound selected from the group consisting of 
Compound 1, Compound 2, Compound 8, Compound 9 and 
Compound 10 above, or a pharmaceutically acceptable salt 
thereof. 
In yet another aspect, the present invention provides a 
pharmaceutical composition for antioxidant or anti-in?am 
matory treatment of a human or other mammal Which com 
prises a compound of Formula I or Formula II above, or a 
pharmaceutically acceptable salt thereof, together With one or 
more pharmaceutically acceptable carriers and/ or diluents. 
In a particular embodiment, the invention provides a 
method of antioxidant or anti-in?ammatory treatment of a 
human or other mammal, Which comprises administration to 
said human or other mammal of a therapeutically effective 
amount of a compound selected from the group consisting of 
Compound 1, Compound 2, Compound 8, Compound 9 and 
Compound 10 above, or a pharmaceutically acceptable salt 
thereof, together With one or more pharmaceutically accept 
able carriers and/ or diluents. 
The present invention also provides the use of a compound 
of Formula I or Formula II above, or a pharmaceutically 
acceptable salt thereof, in the manufacture of a composition 
for antioxidant or anti-in?ammatory treatment of a human or 
other mammal. 
In a particular embodiment, the present invention provides 
the use of a compound selected from the group consisting of 
Compound 1, Compound 2, Compound 8, Compound 9 and 
Compound 10 above, or a pharmaceutically acceptable salt 
thereof, in the manufacture of a composition for antioxidant 
or anti-in?ammatory treatment of a human or other mammal. 
Throughout this speci?cation and the claims Which folloW, 
unless the context requires otherWise, the Word “comprise”, 
and or variations such as “comprises” or “comprising”, Will 
be understood to imply the inclusion of a stated integer or step 
or group of integers or steps but not the exclusion of any other 
integer or step or group of integers or steps. 
Reference to any prior art in this speci?cation is not, and 
should not be taken as, an acknowledgment or any form of 
suggestion that this prior art forms part of the common gen 
eral knowledge in any country. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1: HPLC analysis of C. cunninghamii extract (CS) 
CI(l0-95). 
FIG. 2: HPLC analysis of C. cunninghamii BG (2-35). 
FIG. 3:TIC and EICs for P6 and P4 from fresh C. cunning 
hamii Extract. 
FIG. 4: (A) MS for P4 (m/Z 495) and (B) Aglycone (m/Z 
333) and P6 (m/Z 546). 
FIG. 5: UV and MS spectra for P4. 
FIG. 6: UV and MS spectra for P6. 
FIG. 7: MS data for P4 Glycosidase and Aglycone. 
FIG. 8: Isolation scheme for anti-in?ammatory and anti 
oxidant compounds from C. cunninghamii. 
FIG. 9: Compounds isolated from C. cunninghamii. 
DETAILED DESCRIPTION OF THE INVENTION 
With reference to the monosaccharide or disaccharide 












ferred monosaccharide groups include groups derived from 
the pentose sugars D-ribose, D-arabinose and D-xylose and 
the hexose sugars D-glucose, D-mannose, D-galactose and 
D-fructose. Preferred disaccharide groups include groups 
derived from sucrose, lactose and maltose. Particularly pre 
ferred monosaccharide groups are [3-D-glucopyranoside 
groups of Formula III: 
(III) 
Wherein R is de?ned above. 
In Formula I and Formula II herein: 
The term “alkyl” refers to a straight or branched hydrocar 
bon chain radical consisting solely of carbon and hydrogen 
atoms, containing no unsaturation, having from one to eight 
carbon atoms, and Which is attached to the rest of the mol 
ecule by a single bond, e.g., methyl, ethyl, n-propyl, l-meth 
ylethyl (isopropyl), n-butyl, n-pentyl, l,l-dimethylethyl 
(t-butyl), and the like. 
The term “cycloalkyl” denotes a non-aromatic mono or 
multicyclic ring system of about 3 to 12 carbon atoms such as 
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and 
examples of multicyclic cycloalkyl groups include perhy 
dronaphthyl, ademantyl and norbornyl groups bridged cyclic 
group or sprirobicyclic groups, e.g. spiro (4,4) non-2-yl. 
The term “cycloalkylalkyl” refers to a cycloalkyl group as 
de?ned above directly attached to alkyl group Which is then 
attached to the main structure at any carbon from alkyl group 
that results in the creation of a stable structure such as cyclo 
propylmethyl, cyclobutylethyl, cyclopentylethyl, and the 
like. 
The term “alkoxy” refers to an alkyl group as de?ned above 
attached via an oxygen linkage to the rest of the molecule, 
such as 4OCH3, 4OC2H5 and the like. 
The term “aryl” refers to aromatic radicals having in the 
range of 6 up to 14 carbon atoms such as phenyl, naphthyl, 
tetrahydronaphthyl, indanyl, biphenyl and the like. 
The term “arylalkyl” refers to an aryl group as de?ned 
above directly bonded to an alkyl group as de?ned above, e. g., 
4CH2C6H5, iC2H5C6H5 and the like. 
Substituents in the “substituted alkyl”, “substituted 
cycloalkyl”, “substituted cycloalkylalkyl”, “substituted ary 
lalkyl” or “substituted aryl” groups may be the same or dif 
ferent, and may be selected from groups such as hydrogen, 
hydroxy, halogen, carboxyl, cyano, nitro, oxo (:O), thio 
(:S), substituted or unsubstituted alkyl, substituted or 
unsubstituted alkoxy, substituted or unsubstituted aryl, sub 
stituted or unsubstituted arylalkyl, substituted or unsubsti 
tuted cycloalkenyl, substituted or unsubstituted amino, 
4COOR", 4C(O)R", 4C(S)R", iC(O)NR"Ry, 4C(O) 
ONRxRy, iNRxCONRyRZ, iN(R")SORy, iN(R")SO2Ry, 
i(:NiN(R")Ry, iNRxC(O)ORy, iNRxRy, iNRxC(O) 
iR‘ORy, iR‘C(O)ORy, iRxC(O)NRyRZ, iRxC(O)R", 
iRxOC(O)Ry, iSR", iSOR", iSOzR", and ADNO2, 
Wherein R", Ry and R2 in each of the above groups can be 
hydrogen atom, substituted or unsubstituted alkyl, substituted 
or unsubstituted alkoxy, substituted or unsubstituted aryl, 
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substituted or unsubstituted arylalkyl, substituted or unsub 
stituted cycloalkyl, or substituted or unsubstituted amino. 
Pharmaceutically acceptable salts include salts derived 
from inorganic bases such as Li, Na, K, Ca, Mg, Fe, Cu, Zn, 
Mn; salts of organic bases such as N,N'-diacetylethylenedi 
amine, glucamine, triethylamine, choline, dicyclohexy 
lamine, metformin, benZylamine, trialkylamine, thiamine, 
and the like; chiral bases like alkylphenylamine, glycinol, 
phenyl glycinol and the like, salts of natural amino acids such 
as glycine, alanine, valine, leucine, isoleucine, norleucine, 
tyrosine, cystine, cysteine, methionine, proline, hydroxy pro 
line, histidine, omithine, lysine, arginine, serine and the like; 
quaternary ammonium salts of the compounds of invention 
With alkyl halides, alkyl sulphats like Mel, (Me)2SO4 and the 
like, non-natural amino acids such as D-isomers or substi 
tuted amino acids; guanidine, substituted guanidine Wherein 
the substituents are selected from nitro, amino, alkyl, alkenyl, 
alkynyl, ammonium or substituted ammonium salts and alu 
minium salts. Salts may include acid addition salts Where 
appropriate Which are sulphates, nitrates, phosphates, per 
chlorates, borates, hydrohalides, acetates, tartrates, maleates, 
citrates, fumarates, succinates, palmoates, methanesulpho 
nates, benZoates, salicylates, benZenesulfonates, ascorbates, 
glycerophosphates, ketoglutarates and the like. 
As used herein, “treating” or “treatment” of a state, disor 
der or condition includes: 
(1) preventing or delaying the appearance of clinical symp 
toms of the state, disorder or condition developing in a 
human or other mammal that may be afflicted with or 
predisposed to the state, disorder or condition but does not 
yet experience or display clinical or subclinical symptoms 
of the state, disorder or condition; 
(2) inhibiting the state, disorder or condition, i.e., arresting or 
reducing the development of the disease or at least one 
clinical or subclinical symptom thereof; or 
(3) relieving the disease, i.e., causing regression of the state, 
disorder or condition or at least one of its clinical or sub 
clinical symptoms. 
The bene?t to a subject to be treated is either statistically 
signi?cant or at least perceptible to the patient or to the 
physician. 
A “therapeutically effective amount” means the amount of 
a compound that, When administered to a human or other 
mammal for treating a state, disorder or condition, is su?i 
cient to effect such treatment. The “therapeutically effective 
amount” Will vary depending on the compound, the disease 
and its severity and the age, Weight, physical condition and 
responsiveness of the mammal to be treated. 
(1) Compounds. 
In one aspect, the present invention provides an isolated 
compound selected from the group consisting of Compound 
1, Compound 2, Compound 8, Compound 9 and Compound 
10 above, in substantially puri?ed form, or a pharmaceuti 
cally acceptable salt thereof. These compounds may be iso 
lated from plant material and extracts of C. cunninghamii by 
methods described in the Examples herein. 
The term “isolated” means that the compound is substan 
tially or essentially freed from components that normally 
accompany it in its native state in C. cunninghamii by at least 
one puri?cation or other processing step. Such a compound 
may also be described as substantially pure. The term “sub 
stantially pure” as used herein describes a compound that has 
been separated from components that naturally accompany it. 
Typically, a compound is substantially pure When at least 
50%, more preferably at least 70% or 80%, even more pref 
erably at least 90%, and most preferably at least 95% or even 












by mole percent or mole fraction) is the compound of interest. 
Purity can be measured by any appropriate method, for 
example by chromatography, gel electrophoresis or HPLC 
analysis. 
In another aspect, the present invention provides a com 
pound of Formula I or Formula II, or a pharmaceutically 
acceptable salt thereof. 
Compounds of Formula I or Formula II may be synthesised 
from the compounds isolated from plant material and extracts 
of C. cunninghamii, by methods Which are Well knoWn to 
skilled chemists in this ?eld. 
(2) Formulations 
The present invention also extends to pharmaceutical com 
positions for antioxidant or anti-in?ammatory treatment of a 
human or other mammal Which comprise a compound of 
Formula I or Formula II as described above, or a pharmaceu 
tically acceptable salt thereof, together With one or more 
pharmaceutically acceptable carriers and/or diluents. 
The invention also extends to the use of a compound of 
Formula I or Formula II as described above, or a pharmaceu 
tically acceptable salt thereof, in the manufacture of a com 
position for antioxidant or anti-in?ammatory treatment of a 
human or other mammal. 
The formulation of such therapeutic compositions is Well 
knoWn to persons skilled in this ?eld. Suitable pharmaceuti 
cally acceptable carriers and/or diluents include any and all 
conventional solvents, dispersion media, ?llers, solid carri 
ers, aqueous solutions, coatings, antibacterial and antifungal 
agents, isotonic and absorption delaying agents, and the like. 
The use of such media and agents for pharmaceutically active 
substances is Well knoWn in the art, and it is described, by Way 
of example, in Remington ’s Pharmaceutical Sciences, 18th 
Edition, Mack Publishing Company, Pennsylvania, USA. 
Except insofar as any conventional media or agent is incom 
patible With the active ingredient, use thereof in the pharma 
ceutical compositions of the present invention is contem 
plated. Supplementary active ingredients can also be 
incorporated into the compositions. 
It is especially advantageous to formulate such composi 
tions in dosage unit form for ease of administration and uni 
formity of dosage. Dosage unit form as used herein refers to 
physically discrete units suited as unitary dosages for the 
human or other mammalian subjects to be treated; each unit 
contains a predetermined quantity of active ingredient calcu 
lated to produce the desired therapeutic effect in association 
With the required pharmaceutical carrier and/ or diluent. The 
speci?cations for the novel dosage unit forms of the invention 
are dictated by and directly dependent on (a) the unique 
characteristics of the active ingredient and the particular 
therapeutic effect to be achieved, and (b) the limitations 
inherent in the art of compounding such an active ingredient 
for the particular treatment. 
(3) Administration 
The present invention further extends to the methods for 
antioxidant or anti-in?ammatory treatment of a human or 
other mammal by administering a therapeutically effective 
amount of a compound of Formula I or Formula II as 
described above or a pharmaceutically acceptable salt 
thereof. 
Preferably, this treatment is administered to a human or 
other mammal in need of therapeutic or prophylactic treat 
ment for a disease condition or potential disease condition. 
Most preferably, the treatment is treatment of a human. 
Antioxidants are attracting considerable research interest 
With respect to their actual or potential role in the prevention 
or treatment of a Wide range of mostly chronic conditions, 
including cardiovascular diseases (incl. atherosclerosis), dia 
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betes, Alzheimer disease, systemic in?ammatory disorders 
and cancer. As used herein, the term “antioxidant treatment” 
relates to prevention or treatment of disease conditions such 
as those described Where compounds With antioxidant activ 
ity have an actual or potential role in prevention or treatment 
of the condition. 
The term “anti-in?ammatory treatment” as used herein 
relates to treatment of in?ammatory conditions in general, 
including arthritic conditions having an in?ammatory com 
ponent such as osteoarthritis and rheumatoid arthritis, as Well 
as treatment of other disease conditions involving in?amma 
tion such as multiple sclerosis. 
A variety of administration routes are available. The par 
ticular mode selected Will depend, of course, upon the par 
ticular condition being treated and the dosage required for 
therapeutic ef?cacy. The methods of this invention, generally 
speaking, may be practised using any mode of administration 
that is medically acceptable, meaning any mode that produces 
therapeutic levels of the active component of the invention 
Without causing clinically unacceptable adverse effects. Such 
modes of administration include parenteral (e.g. subcutane 
ous, intramuscular and intravenous), oral, rectal, topical, 
nasal and transdermal routes. 
The active component may conveniently be presented in 
unit dosage form and suitable compositions for administra 
tion may be prepared by any of the methods Well knoWn in the 
art of pharmacy. Such methods include the step of bringing 
the active component into association With a carrier and/or 
diluent Which may include one or more accessory ingredients. 
In general, the compositions are prepared by uniformly and 
intimately bringing the active component into association 
With a liquid carrier, a ?nely divided solid carrier, or both, and 
then, if necessary, shaping the product. 
Compositions suitable for parenteral administration con 
veniently comprise a sterile aqueous preparation of the active 
component Which is preferably isotonic With the blood of the 
recipient. This aqueous preparation may be formulated 
according to knoWn methods using those suitable dispersing 
or Wetting agents and suspending agents. The sterile inject 
able preparation may also be a sterile injectable solution or 
suspension in a non-toxic parenterally-acceptable diluent or 
solvent, for example as a solution in polyethylene glycol and 
lactic acid. Among the acceptable vehicles and solvents that 
may be employed are Water, Ringer’s solution and isotonic 
sodium chloride solution. In addition, sterile, ?xed oils are 
conventionally employed as a solvent or suspending medium. 
For this purpose, any bland ?xed oil may be employed includ 
ing synthetic mono- or di-glycerides. In addition, fatty acids 
such as oleic acid ?nd use in the preparation of injectables. 
Compositions of the present invention suitable for oral 
administration may be presented as discrete units such as 
capsules, cachets, tablets or loZenges, each containing a pre 
determined amount of the active component, in liposomes or 
as a suspension in an aqueous liquor or non-aqueous liquid 
such as a syrup, an elixir, or an emulsion. 
Other delivery systems can include sustained release deliv 
ery systems. Preferred sustained release delivery systems are 
those Which can provide for release of the active component 
of the invention in sustained release pellets or capsules. Many 
types of sustained release delivery systems are available; 
these include, but are not limited to: (a) erosional systems in 
Which the active component is contained Within a matrix, and 
(b) diffusional systems in Which the active component per 
meates at a controlled rate through a polymer. 
The active component is administered in therapeutically 
effective amounts. A therapeutically effective amount means 












effect, or to delay the onset of, inhibit the progression of, or 
halt altogether, the onset or progression of the particular 
condition being treated. Such amounts Will depend, of course, 
on the particular condition being treated, the severity of the 
condition and individual patient parameters including age, 
physical condition, siZe, Weight and concurrent treatment. 
These factors are Well knoWn to those of ordinary skill in the 
art and can be addressed With no more than routine experi 
mentation. It is preferred generally that a maximum dose be 
used, that is, the highest safe dose according to sound medical 
judgement. It Will be understood by those of ordinary skill in 
the art, hoWever, that a loWer dose or tolerable dose may be 
administered for medical reasons, psychological reasons or 
for virtually any other reasons. 
Generally, daily oral doses of active component Will be 
from about 0.01 mg/kg per day to 1000 mg/kg per day. Small 
doses (0.01-1 mg) may be administered initially, folloWed by 
increasing doses up to about 1000 mg/kg per day. In the event 
that the response in a subject is insu?icient at such doses, even 
higher doses (or effective higher doses by a different, more 
localised delivery route) may be employed to the extent 
patient tolerance permits. Multiple doses per day are contem 
plated to achieve appropriate systemic levels of compounds. 
Further features of the present invention are more fully 
described in the folloWing Example(s). It is to be understood, 
hoWever, that this detailed description is included solely for 
the purposes of exemplifying the present invention, and 
should not be understood in any Way as a restriction on the 
broad description of the invention as set out above. 
EXAMPLE 1 
Preparation of C. cunninghamii Extracts. 
1.2.1. Materials 
The analytical balance Was from Mettler Toledo (AG 285), 
the grinder Was a Kika (MF10 basic) With 4000 rpm. The 
sonicator used Was from Ultrasonic and the centrifuge from 
Hettich Universal (16A). The rotavapor Was a Buchi R-114. 
Milli Q Water Was obtained by ?ltration With 0.22 um Milli 
pore. The extraction solvent Was ethanol and Was purchased 
from Aldrich (HPLC grade) and DMSO (dimethylsulphox 
ide) SIGMA D-5879. The LCMS instrument used Was an 
Agilent 1100 Series HPLC With a Phenomenex “aqua” C18 
5 p. 150><4.6 mm HPLC column. The column temperature Was 
400 C. The UV data Was obtained by an Agilent 1100 series 
Diode Array UV/V IS Detector and the mass spectra by the 
HeWlett Packard 1100 Series Mass Selective Detector, The 
mass spectrometer conditions Were drying gas ?oW: 5 L/min, 
nebuliZer pressure at 60 psig, vaporiZer temperature: at 4000 
C., mass range at 100-1350 amu, Fragmentor voltage at 150 
V, mode at scan and the polarity Was positive. The HPLC 
solvents Were acetonitrile (HPLC grade) purchased from 
LAB-SCAN (C-3502 U) and Milli Q Water. For preparative 
purposes the Gilson HPLC system With 306 pump, a 
UV/VIS-155 detector, anAlltima Cl 8 column (22><1 50 mm, 5 
pm) and an attached EC 204 fraction collector Was used. To 
dry the samples a Christ Alpha 2-4 and a Christ Alpha RVC 
Were used. NMR spectra Were acquired on a BrukerAVANCE 
DRX500 (1H, 500.13 MHZ; 13C, 125.77 MHZ) spectrometer. 
1 .22. Extract Preparation 
The entire Cenlipeda cunninghamii plant Was harvested 
for extraction. Samples of plant material Were deposited in 
the Medicinal Plant Herbarium at Southern Cross University 
(NCM-D-04-113 and NCM-D-05-008). The plant material 
Was chopped and dried for storage until needed. It Was then 
ground using the Kika grinder to get a su?iciently small 
particle siZe to promote ef?cient contact With the solvent. One 
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part plant material Was mixed With ?ve parts of 45/ 55 ethanol/ 
Water as a solvent. TWo different extraction procedures Were 
compared; maceration, With or Without sonication. The 
resulting extract Was dark reddish-broWn. The dried extract 
Was dark broWn and hygroscopic. 
1.2.2.1. Extracts for LCMS 
An extract of ratio 1:5 (plant materialzsolvent) Was pre 
pared. TWo vials each With 1 g of plant material Were prepared 
and 5 mL of 45% ethanol added. One vial Was sonicated for 
10 minutes (CS) and one not (C). Both Were steeped for 24 
hours. The extract Was centrifuged at 3000 rpm for 10 minutes 
and the clear supernatant used to run a pro?le on the LCMS 
(see FIG. 1). A larger extract Was made for preparative HPLC 
using the same extraction technique. 
1.2.2.2. Extracts for Pharmacology 
The same extraction procedure Was used as above. The 
solution obtained Was taken to dryness on the rotary evapo 
rator under vacuum. See Table 1 for extraction yield. 
TABLE 1 
Extraction Yield of C. cunninghamii 
Extract Solvent Yield CS (g) Yield C (g) 
45% ethanol 0.0614 0.0776 
The dried extracts Were dissolved using acetone and trans 
ferred to a 25 mL screW top vial and dried With N2. The dried 
extracts Were reconstituted for pharmacological assays. For 
the ORAC (oxygen radical absorbance capacity) assay 75% 
ethanol Was used as a solvent. For the other assays 100% 
DMSO (dimethyl sulphoxide) Was used instead of ethanol. 
Different concentrations of C. cunninghamii extract Were 
prepared and stored in the freeZer at —200 C. 
1.2.3. Identi?cation and Isolation of Compounds With HPLC 
To identify and quantify the constituents of the extracts 
pro?les Were generated using Liquid Chromatography/Mass 
Spectrometry (LCMS). The stationary phase Was a RP-C18 
column consisting of silica based packing With a covalently 
bound octadecyl ligand. The mobile phase Was Water and 
acetonitrile (ACN) both containing 0.05% tri?uoroacetic acid 
(TFA). 
The HPLC had an UV detector, Which measured the ability 
of a compound to absorb light at a speci?c Wavelength. The 
instrument used had a Diode Array detector (DAD) Which 
scanned Wavelengths from 190 nm to 800 nm for each peak. 
The data Were displayed at 210 nm, 280 nm and 360 nm. 
A Mass Selective (MS) detector Was attached, Which gave 
information on the mass of compounds and fragmentation 
patterns. The molecule Was ioniZed using an APCl (atmo 
spheric pressure chemical ionization) spray chamber and then 
passed through a mass selective detector Where the ion cur 
rent Was detected. 
1.2.3.1. HPLC Methods 
Three different HPLC methods Were used: 
CI (10-95) 
A gradient ranging from 90% to 5% Water With ACN over 
30 minutes Was used for the preliminary pro?les. FloW rate 
Was 1 mL/min, the injection volume 10 pL and stop time 45 
minutes. 
CI (10-95) M 
A gradient ranging from 90% to 5% Water With ACN over 
18 minutes Was used for the preliminary pro?les. FloW rate 














A gradient ranging from 98% to 65% Water With ACN over 
20 minutes Was used. Stop time Was 40 minutes.At the LCMS 
the How rate Was 1 mL/min and the injection volume Was 10 
uL. On the preparative HPLC the How rate Was 25 mL/min 
and injection volume 1 mL. 
LCMS pro?les of the different extracts of C. cunninghamii 
Were made. The CI (10-95) method Was used. The HPLC 
trace at 210 nm and the Total Ion Chromatogram (TIC) are 
shoWn in FIG. 1. There Was no difference in the HPLC traces 
betWeen the sonicated and the non-sonicated extract. 
TABLE 2 
Retention Time and Mass of the Major 
Peaks in C. cunnirghamii CI (10-95) 
Peak Nr. Retention Time (min) Mass [M + 1]* m/Z 
4 8.2 495 
5 8.5 499 
6 8.7 546 
8 1 1.6 333 
The crude ethanol extract Was separated by preparative 
HPLC to obtain pure compounds for identi?cation by NMR. 
To prepare enough material preparative columns Were uti 
liZed. The prep-column had column dimensions of 22><150 
mm Which Was designed to facilitate large volume injections 
into the HPLC system. One gram extract Was dissolved in 10 
mL 50:50 Water and ACN. The injection volume Was 1 mL 
Which gave the total amount of 100 mg extract on the column. 
The system used Was a Gilson HPLC system Which had an 
automatic fraction collector attached Which Was programmed 
to collect 30 second fractions. 40 fractions Were collected per 
run. As the main peaks of interest Were peak 4 and 6 a neW 
method Was developed Which shoWed a better separation in 
this particular area. The method Was BG (2-35) and the HPLC 
trace is shoWn in FIG. 2. 
To obtain enough material for the NMR tWo runs Were 
performed and after purity checks on the LCMS the fractions 
Were combined. The gradient method used on the LCMS Was 
CI (10-95) M. 
To collect peak 4 and peak 6 more runs Were made With the 
same method. After purity checks on the LCMS fraction 8 
Was found to be pure and identi?ed as peak 6 With [M+1]+ of 
546. Fraction 3 Was identi?ed as peak 4 With [M+1]+ of 495. 
The fractions Were taken to dryness on the rotary evaporator 
and then further dried on the RVC. The yield of peak 6 Was 
13.0 mg and ofpeak 4 12.1 mg. 
EXAMPLE 2 
Active Constituents of C. cunninghamii. 
Fresh ethanolic extracts of C. cunninghamii Were subjected 
to bioassay guided fractionation using preparative HPLC on 
C18 as described in Example 1. One minute fractions Were 
cut and pooled according to the HPLC pro?le using the detec 
tor response at 210 nm. The raW data is summarised beloW. 
TABLE 3 
Description of Samples 
Sample Description 
E1 Fractions 1-6 
E2 Fractions 7-12 
E3 Fractions 13-16 
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TABLE 3-continued 
Description of Samples 
Sample Description 
E4 Fractions 17-24 
E5 Fractions 25-29 
E6 Fractions 30-35 
E7 Fractions 3 6-40 
P4 Puri?ed Compound 1 
P6 Puri?ed Compound 2 
EXAMPLE 3 
Identi?cation of Active Constituents 
TWo novel compounds With con?rmed biological activity 
Were isolated and identi?ed in the fresh C. cunninghamii 
extract and these Were identi?ed as P4 (Compound 1) and P6 
(Compound 2) based on NMR and MS data. 
Compound 1 or P4 elutes at 8.3 minutes and is character 
ised by the EIC (Extracted Ion Chromatogram, FIG. 3) using 
m/Z 495 (the parent ion plus H, M+H or M+1) as shoWn in 
FIG. 4A. Chemical data for P4 are set out beloW, and NMR 
spectral data are set out in Table 4. UV and MS spectra for P4 
are shoWn in FIG. 5. 
Chemical Name: 5,7,2‘,4’—tetrahyd.roxy—6—methoxy?avone—3-O— 
[5-glucopyranoside 
Molecular Formula: C22H22Ol3 
Molecular Weight: 494 




1H (500.13 MHZ) and 13c (125.77 MHZ) 
NMR spectral data for P4 in methanol—dA. 
Chemical Shift ppm 
Position C/H 1H” 













lH (500.13 MHZ) and 13c (125.77 MHZ) 
NMR spectral data for P4 in methanol-d4. 
Chemical Shift, ppm 
Position C/H 1HQ 130 
5' 7.59 dd (2.2, 8.5) 123.4 
6' 6.87 d (8.5) 116.2 
1" 5.26 d (7.6) 104.4 
2" 3.49 dd (7.6, 9.1) 75.9 
3" 3.43 dd (8.7, 9.1) 78.3 
4" 3.35 dd (8.7, 9.6) 71.4 
5" 3.22 ddd (2.4, 5.4, 9.6) 78.5 
6" 3.70 dd (2.4, 11.9) 62.7 
3.57 dd (5.4, 11.9) 
4OCH3 3.88 s 61.1 
“Values in parentheses are coupling constants in Hz. 
Optical rotation (Compound P4) [01]A — 12.53 (C = 0.06, MeOH) T = 21 .00 C. 
Compound 2 or P6 elutes at 8.7 minutes and is character 
ised by the EIC (Extracted Ion Chromatogram, FIG. 3) using 
m/Z 546 (the parent ion plus H, M+H or M+1) as shoWn in 
FIG. 4B. Compound P6 shoWed a major fragment ion at m/Z 
349 attributed to the loss of cinnamoyl ester and Water. 
Chemical data for P6 are set out beloW, and NMR spectral 
data are set out in Table 5. UV and MS spectra for P6 are 
shoWn in FIG. 6. 
Molecular Formula: C25H22O14 
Molecular Weight: 546 
Optical Rotation, [0t]D: +23.5394 (Conc.: 0.3300 in methanol at 
23.70 0.) 
Chemical Structure: 





1H (500.13 MHZ) and 13c (125.77 MHZ) 
NMR spectral data for P6 in methanol-d4. 
Chemical Shift ppm 
Position C/H 1H(1 13c 
1 i 164.8 
2 i 146.1 
3 6.02 dd (2.1, 1.8) 109.3 
4 5.98,m 65.3 
5 5.98,m 66.4 
6 5.14, s 76.4 
7 i 170.2 
1'/1" i 167.9/168.0 
272" 6.31, d (15.9)/6.16, d (15.9) 114.1/114.3 
3'/3" 7.49, d (15.9)/7.53, d (15.9) 1481/1486 
474" i 127.7/127.7 
5'/5" 6.99 d (2.1 )/7.03, d (2.1) 115.1/115.4 
6'/6" i 147.0/147.0 
7'/7" i 149.9/1500 
8'/8" 6.69 d (8.2)/6.76 d (8.2) 116.6/1167 
979" 6.91 dd (2.1, 8.2)/6.81 dd (2.1, 8.2) 123.6/123.7 
“Values in parentheses are coupling constants in Hz. 
Optical rotation (Compound P6) [0r]A + 46.24 (C = 0.375, MeOH) T = 21.50 C. 
EXAMPLE 4 
Antioxidant and Anti-in?ammatory Activity of Active Con 
stituents. 
The antioxidant activity in the plant material was measured 
using the ORAC assay and the trolox equivalent value TE/ g 
dried extract was determined. The highest activity was found 
in the non-sonicated extract of C. cunninghamii (C) with a 
TE/g of 7404. The extracts showed decreased antioxidant 
activity when sonicated. 
The anti-in?ammatory assay performed measured the level 
of prostaglandin PGE2. The fresh C. cunninghamii extracts, 
both non-sonicated and sonicated, showed a strong dose 
response effect and possessed a higher inhibition of PGE2 
production than the positive control aspirin. The IC5O value of 
sonicated extract was 0.097 mg/mL and the IC5O of non 
sonicated extract was 0.105 mg/mL. The results of these 
assays are set out in Tables 6 and 7 below. 
TABLE 6 
Inhibition of PGE7 production of Cenripeda fractions. 
Concentration of sample % inhibition of PGE2 
Sample (mgmL) production 1 SEM 
E1 0.125 72.04 1 5.50 
E2 0.0625 75.51 1 6.90 
E3 0.125 76.33 1 2.61 
E4 0.0625 94.29 1 0.74 
E5 0.0625 —26.94 1 28.07 
E6 0.125 70.61 1 4.08 
E7 0.0625 80.10 1 7.04 
P4 0.125 67.76 1 2.86 
P6 0.0625 74.49 1 8.06 
Aspirin 0.01 mM 57.35 1 14.42 
Samples were tested for their ability to inhibit prostaglan 
din E2 production in cells stimulated by a calcium ionophore, 
compared to stimulated cells not exposed to any sample. 
Inhibition was tested over a range of 3 concentrations, 
although a dose response was not observed for most samples. 
This is probably because the samples are very ef?cient at 
inhibiting PGE2 production and the range of concentrations 
used was too narrow. The data presented are the maximal 











Antioxidant capacity of Cenripeda fractions. 










The antioxidant capacity of the Cenlipeda fractions was 
measured using the ORAC procedure (Oxygen Radical 
Absorbance Capacity). A water soluble analogue of vitamin 
E, Trolox, was used as a reference standard, and the ORAC 
value is expressed as umol of trolox equivalence (TE) per 
gram of sample extract. 
EXAMPLE 5 
5 .1 Methods 
Preparative HPLC was used to fractionate the crude 
extracts of C. cunninghamii into 30 or more fractions in a 
precise and repeatable manner. Fractionation of extracts was 
performed on a Gilson Preparative HPLC system employing 
a Gilson 322 binary pump system, a Gilson 156 UV-Vis dual 
wavelength detector and Gilson fraction collector (FC204). 
Separation was done by gradient elution with varying com 
positions of acetonitrile (solvent B) and water (solvent A). 
The prep HPLC operation is software driven using Gilson 
Unipoint v.3.0, and the details of the program and gradient 
timetable for the methods used for each extract is given below. 
The fractions were dried using a Rotary Evaporator Centri 
fuge (RVC) and combined as appropriate after veri?cation by 
LCMS. 
5.1.1 Initial Fractionation of Crude Extract. 
Mobile Phase Gradient Timetable KB10-95 and BI10-95. 
Method: 
Time (min) % A % B Flow Rate (mL/min) 
0 90 10 15.0 
25 10 90 15.0 
28 10 90 15.0 
30 90 10 15.0 
35 90 10 15.0 
5.1.2 Sub-fractionation of C. cunninghamii Fraction 2. 
Mobile Phase Gradient Timetable BI10-25. Method: 
Time (min) % A % B Flow Rate (mL/min) 
0 90 10 15 
15 75 25 15 
18 90 10 15 
20 90 10 15 
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5.1.3 Sub-fractionation of C. cunninghamii Fraction 11 and 
14. 
Mobile Phase Gradient Timetable B120-40. Method: 
Time (min) % A % B FloW Rate (mL/rnin) 
0 80 20 15 
15 60 40 15 
18 80 20 15 
20 80 20 15 
5.1.4 Sub-fractionation of C. cunninghamii Fraction 16 and 
17. 
Mobile Phase Gradient Timetable KB20-50. Method: 
Time (min) % B FloW Rate (mL/rnin) 
0 80 20 15 
15 50 50 15 
16 5 95 15 
20 5 95 15 
21 20 20 15 
23 20 20 15 
5.1.5 Fractionation of C. cunninghamii FloWers Ethanol Par 
tition. 
Mobile Phase Gradient Timetable KB20-60. Method: 
Time (min) % A % B FloW Rate (mL/rnin) 
0 80 20 15 
20 40 60 15 
23 40 60 15 
25 80 20 15 
28 80 20 15 
5.1.6 Fractionation of C. cunninghamii FloWers Hexane Par 
tition. 
Mobile Phase Gradient Timetable KB50-80. Method: 
Time (min) % A % B FloW Rate (mL/rnin) 
0 60 40 15 
16.4 25 75 15 
20 25 75 15 
21 10 90 15 
28 10 90 15 
30 60 40 15 
33 60 40 15 
5.2 Solid Phase Extraction (SPE) 
SPE cartridges Were used to rapidly partition the bulk of the 
crude plant extract into four fractions. Supelco, 60 mL SPE 
columns packed With 10 grams of Supelclean LC-18 Were 
used. The 10 grams of sorbent generates a bed volume (BV) 
of 20 mL and a maximum sample loading capacity of 500 mg. 
SPE columns Were ?rst pre-Wet With 6-10BV of methanol 
and then preconditioned using 6-10 BV of Water. 500 mg of 
the extract Was ?rst dissolved in 1 BV of the starting mobile 
phase and loaded onto the SPE column. The sample Was then 









Fraction Solvent Volume 
1 100% Water 60 mL 
2 20% ACN/Water 60 mL 
3 40% ACN/Water 60 mL 
4 100% ACN 60 rnL 
5.3 Pharmacology 
5 .3 .1 Sample Preparation 
The extracts Were stored at 40 C. prior to analysis. The 
extracts Were re-solubilised in solvent by sonicating for 20 
minutes. 
5.3.2 Oxygen Radical Absorbance Capacity (ORAC) 
The ORAC assay employed in this study measured the 
antioxidant scavenging activity in the test samples, against 
peroxyl radicals induced by 2,2'-aZobis(2-amidinopropane) 
dihydrochloride (AAPH) at 37° C. Fluorescein Was used as 
the ?uorescent probe. The method used is based on that of 
Huang et all, Huang et al.2 and Prior et al.3 
1 Huang et al., 2002. Joumal of Agricultural and Food Chemistry 50(16): 
1815-1821. 
2 Huang et al., 2002. Joumal of Agricultural and Food Chemistry 50(16): 
4437-4444. 
3 Prior et al., 2003. Journal ofAgricultural and Food Chemistry 51(11): 3273 
3279. 
All samples Were assayed using the hydrophilic ORAC 
procedure in serial dilution><4 With acetone:Water: acetic acid; 
70:29.5:05 (A:W:A,) and in quadruplicate, starting With the 
concentration relevant to the sample, depending on the 
approximated antioxidant capacity from an initial screen. 
Trolox, a Water soluble analogue of vitamin E, Was used as 
a reference standard. A trolox standard curve Was established 
from trolox standards prepared at 100, 50, 25, and 12.5 uM in 
A:W:A. 
Brie?y, 10 pL ?uorescein (6.0><10_7 M), 20 pL samples/ 
standards/control/blank (A:W:A) and 170 pL MPH (20 mM) 
Were added per Well. Immediately after loading, the plate Was 
transferred to the plate reader preset to 37° C., and the ?uo 
rescence Was measured 35 times at one minute intervals. The 
?uorescence readings Were referenced to solvent blank Wells. 
The ?nal ORAC values Were calculated using a regression 
equation betWeen the Trolox concentration and the net area 
under the ?uorescein decay curve, and Where possible Were 
expressed as Trolox equivalents (TE) as micromoles per gram 
of sample. 
5.3.3 Inhibition of Prostaglandin E2 Production 
3T3 SWiss Albino ?broblast cell suspension (Phenol-red 
free DMEM With 10% FBS and 2 mM L-glutamine) Was 
plated out into 96-Well tissue culture plates (1 ><105 cells/mL, 
100 uL/Well). The cells Were cultured overnight at 37° C., 5% 
C02. The extracts and fractions Were solubilised in DMSO, 
and diluted appropriately With media so the extracts Were 
tested at a ?nal concentration of 1000, 10, and 1 ug/mL; 5 pL 
of sample Was added to each Well. Cells+samples Were incu 
bated (37° C., 3 hours), before the addition of calcium iono 
phore A23187. FolloWing 20 min incubation, the plate Was 
centrifuged (1000 g, 3 min) and the supematants Were 
removed. Included on the plate Was a positive control (aspi 
rin; 100 uM), and DMSO control, both With and Without 
calcium ionophore A23187. 
The supernatants Were diluted by serial dilution (1:500) in 
enZyme immunoassay (EIA) buffer, and assayed for PGE2 
using the Prostaglandin E2 EIA Monoclonal Kit (Cayman 
Chemical; Cat No. 514010), according to manufacturers’ 
instructions. 
US 8,299,119 B2 
17 
5.4 Isolation and Identi?cation of Compounds Using Chro 
matography and Spectroscopy. 
An overview of the extraction techniques and preparative 
HPLC methods used to isolate pure compounds from C. 
cunninghamii is summariZed in FIG. 8. To isolate the polar 
metabolites a fresh aqueous extract of C. cunninghamii Was 
prepared just prior to fractionation, and the extract Was frac 
tionated by reverse phase preparative HPLC using the Bl(l 0 
95) method outlined above. It Was necessary to sub-fraction 
ate fractions; 2, ll, l4, l6 and 17 using the mobile phase 
gradients as indicated in FIG. 8 to obtain pure compounds. 
Nine compounds have been isolated from the aqueous extract 
as shoWn in FIG. 8. TWo of these compounds, fractions 11 
(Compound 1, ?avonoid glycoside) and 16a (Compound 2), 
had been previously isolated and their identities Were con 
?rmed by their 1H and 13C NMR spectra. 
Fractions 16b/ 17b (Compound 8), l6c/ 17c (Compound 9) 
and 16d (Compound 10) shoWed similar 1H NMR pro?les 
With fraction l6a/l 7a (Compound 2, from previous structural 
elucidation Work) except that additional proton signals Were 
observed in Compounds 8, 9 and 10 that each integrated to 3 
protons. This strongly suggested that Compounds 8, 9 and 10 
are methyl esters of Compound 2 and HMBC data con?rmed 
that Compound 8 Was methylated at the 7-COOH position, 
Compound 9 Was methylated at the l-COOH position and 
Compound 10 Was methylated at both the l- and 7-COOH 
positions as shoWn in their structures beloW. The NMR spec 
tral data of these compounds (2, 8, 9 and 10) are summarised 
in Tables 8 and 9. 
From the results of the bioassay guided fractionation it Was 
observed that the bulk of the anti-in?ammatory activity 
occurs in the region 7-15 minutes in the chromatogram (FIG. 
9) With these compounds only present in small quantities. 
These metabolites predominate in the ?oWers and are present 
at quite loW concentrations. An enriched extract containing 
these compounds Was produced by sieving the ?oWer heads 
(very ?ne petals) from the rest of the plant material. During 
the initial stages of this isolation Work C-1 8 Solid Phase 
Extraction (SPE) cartridges Were used to rapidly partition the 
bulk of the crude plant extract into four fractions. SPE Frac 
tion 3 and 4 contained the compounds of interest. It Was 
necessary to adapt the isolation to a larger scale. The 100% 
aqueous extract described above approximates the SPE frac 
tions 1 & 2. SPE fraction 3 and 4 Were approximated by 
extracting With 100% ethanol folloWed by an ethanol/ hexane 
solvent partition. The ethanol extract of the ?oWers Was back 
extracted With hexane to afford the non-polar compounds. 
The hexane (approximately SPE Fr 4) and the ethanol parti 
tions (approximately SPE Fr 3) Were then evaporated to dry 
ness and subjected to RP-prep HPLC to attain pure com 
pounds. All of the compounds isolated using this scheme are 
indicated on the chromatogram in FIG. 9. 
The compounds obtained from the ethanol partition (FIG. 
8) Were all identi?ed. SPE3-Fraction 1 (Compound 11) Was 
elucidated as the ?avone axillarin and the 1H and 13C NMR 
data are summarised in Table 10. SPE3-fractions 2a (Com 
pound l2), 2b (Compound 13) and 3 (Compound 14) Were all 
deduced to be methoxy derivatives of 4',5,7-trihydroxy ?a 
vones and these Were identi?ed as isokaempferide, 4',5,7 
trihydroxy-3 ,6-dimethoxy-?avone and jaceidin, respectively. 
The structures of these compounds are shoWn beloW and the 
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